Onxeo
49 boulevard du Général Martial Valin
Paris
75015
France
Tel: 33-0-1-45-58-76-00
Fax: 33-0-1-45-58-08-81
Website: http://www.onxeo.com/
Email: contact@onxeo.com
About Onxeo
123 articles about Onxeo
-
Onxeo Reports Third Quarter 2016 Financial Information And Provides Business Update
10/25/2016
-
Onxeo Announces First Outcomes Of Livatag Preclinical Plan
9/13/2016
-
Onxeo: Combination Of Asidna And PARP Inhibitors Demonstrates Synergistic Effect, Bypasses Genetic Restriction
9/7/2016
-
Onxeo To Present At The 18th Annual Rodman & Renshaw Global Investment Conference In New York
9/7/2016
-
Onxeo Reports First-Half 2016 Business Update And Consolidated Financials
7/28/2016
-
Onxeo Signs Exclusive License Agreement With Pint Pharma For The Commercialization Of Beleodaq In PTCL In South America
7/27/2016
-
Onxeo Collaborates With Royal College of Surgeons In Ireland For Research Program On Beleodaq Derivatives
7/8/2016
-
Onxeo Receives USPTO Notice Of Allowance For Key AsiDNA Patent, Extending IP Protection In The U.S. Until 2031
7/5/2016
-
Onxeo Advances Development Plan For First-In-Class Signal Interfering DNA Compound AsiDNA
6/27/2016
-
Onxeo Announces Development Of Beleodaq Oral Formulation Opening New Opportunities For Its HDAC Inhibitor
6/2/2016
-
Onxeo First Quarter 2016 Financial Information And Business Update
4/29/2016
-
Onxeo Final Data From Mechanistic Livatag Study Show Preferential Affinity For Liver, Support Use As Advanced HCC Treatment
4/19/2016
-
Passing On Onxeo’s Extraordinary And Ordinary General Meeting
4/6/2016
-
Onxeo Announces Positive DSMB Recommendation To Continue Livatag Relive Study In HCC
4/4/2016
-
Onxeo Announces Closing Of DNA Therapeutics Acquisition
3/28/2016
-
Onxeo Establishes U.S. Subsidiary
3/21/2016
-
Onxeo Announces The Evolution And Reinforcement Of Its Board Of Directors
1/25/2016
-
Spectrum Pharma And Onxeo Announce Complete Response In 67% Of Patients With Peripheral T-Cell Lymphoma In Combination Of Belinostat (Beleodaq) And Standard CHOP
12/7/2015
-
Onxeo Initiates Comprehensive Strategy To Extend Value Of Key Orphan Oncology Assets
11/19/2015
-
Onxeo Reports Initial Results Of Phase 1 Trial Evaluating Belinostat In Combination With CHOP In Peripheral T-Cell Lymphoma (PTCL)
11/9/2015